Novel therapeutic strategies for treating esophageal adenocarcinoma: the potential of dendritic cell immunotherapy and combinatorial regimens
/in Dendritic Cells, Esophageal Carcinoma, International Publications /von 2008-08-12 / Hum. Immunol. 2008 Oct;69(10):614-24Dendritic cell vaccines in metastasized malignant melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2008-08-01 / G Ital Dermatol Venereol 2008 Aug;143(4):235-50Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients
/in Dendritic Cells, Glioblastoma, International Publications /von 2008-07-15 / Cancer Res. 2008 Jul;68(14):5955-64Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2
/in Breast Cancer, Dendritic Cells, International Publications /von 2008-07-09 / Vaccine 2008 Aug;26(36):4716-24Maximizing dendritic cell migration in cancer immunotherapy
/in Dendritic Cells, International Publications /von 2008-07-01 / Expert Opin Biol Ther 2008 Jul;8(7):865-74Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2008-07-01 / Clin. Cancer Res. 2008 Jul;14(13):4298-305Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha
/in Breast Cancer, Dendritic Cells, International Publications /von 2008-06-27 / BMC Immunol. 2008 Jun;9:32Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International Publications /von 2008-06-16 / Int. J. Urol. 2008 Aug;15(8):694-8Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2008-05-15 / Clin. Cancer Res. 2008 May;14(10):3098-104
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de